期刊
PEDIATRIC INFECTIOUS DISEASE JOURNAL
卷 41, 期 5, 页码 417-419出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0000000000003467
关键词
Hepatitis C; HIV; treatment; adolescents; pediatric; direct-acting antivirals
资金
- Penta Foundation
- ViiV Healthcare
- BMS (Penta Foundation)
- Abbvie
- Bristol Myers Squibb
- Gilead
- Janssen Pharmaceuticals
- ViiV Healthcare (Penta Foundation)
This study evaluated the real-world safety and effectiveness of direct-acting antivirals (DAAs) in HIV/HCV coinfected adolescents from the Ukraine Paediatric HIV Cohort Study. The results showed that DAA treatment was well tolerated and effective in these patients.
Direct-acting antivirals (DAAs) have been approved for treating chronic hepatitis C virus (HCV) in children and adolescents. Although DAAs have been used in real-world settings for the treatment of HCV monoinfected adolescents, few reports of real-world use of DAAs in children and adolescents who are coinfected with human immunodeficiency virus (HIV) are available. We evaluated the real-world safety and effectiveness of DAAs in HIV/HCV coinfected adolescents from the Ukraine Paediatric HIV Cohort Study including all those for whom treatment outcomes were available by April 2021. Overall, 6 coinfected adolescents had received DAA treatment; 4 with sofosbuvir/ledipasvir (SOF/LDV), 1 with SOF/LDV+ribavirin, and 1 with SOF/daclatasvir. No patient discontinued treatment due to adverse events and no serious adverse events were reported. All 6 patients achieved sustained virologic response by 12 weeks after the end of therapy. DAA treatment was well tolerated and effective in adolescents with HIV/HCV coinfection in a real-world setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据